LUPIN

    STUDY TITLE

    Radionuclide therapy using 177Lu-PSMA: a phase I study in men with castrate-resistant prostate cancer to determine the clinical benefit of combination therapy with idronoxil (LuPin trial)
    Phase of study I
    Patient population Males with metastatic castrate resistant cancer of the prostate
    Number of patients/Cohorts 16
    (2 cohorts; 8 per cohort)
    Objectives
    1. Determine safety of combination therapy of NOX66 and 177 Lu-PMSA.
    2. Determine signals of efficacy of 2 doses of NOX66 in combination 177 Lu-PMSA at 2 and 3 months post completion of therapy.
    Countries Australia
    Site/s
    • St Vincent’s Hospital, Sydney
    STATUS Open. Enrolling patients